Navigation Links
Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
Date:1/18/2008

ABBOTT PARK, Ill., Jan. 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today it received approval from the U.S. Food and Drug Administration for its fully automated HTLV-I/HTLV-II blood screening test for use on the ABBOTT PRISM instrument. The test is intended for use by laboratories to screen individual donations of blood and plasma for antibodies to human T -- lymphotropic virus Type I and/or human T -- lymphotropic virus Type II (anti-HTLV-I/HTLV-II).

HTLV-I and HTLV-II are closely related but distinct retroviruses associated with several diseases including human T-cell leukemia and neurological disorders, according to the Centers for Disease Control. Screening of the U.S. blood supply for HTLV-I/II began in 1988.

Used in more than 30 countries, the PRISM system also includes four hepatitis tests: a core hepatitis B test (PRISM HBcore), introduced in October 2005; two hepatitis B surface antigen tests (PRISM HBsAg and HBsAg Confirmatory), introduced in July 2006; and a hepatitis C test (PRISM HCV), introduced in July 2007.

"With the ABBOTT PRISM system, we continue to support the infectious disease testing needs of the laboratory while helping them realize greater efficiencies and enhanced operator safety throughout the blood and plasma screening process," said Robert Doss, Ph.D., divisional vice president, diagnostics research and development, Abbott. "The introduction of the PRISM HTLV-I/HTLV-II test reinforces Abbott's role as a leader in ensuring the safety of the world's blood supply."

In 1985, Abbott developed the first HIV blood-screening test approved in the United States. Today, Abbott's infectious disease tests are used thousands of times every day around the globe for blood screening and diagnostic testing. According to the American Association of Blood Banks (AABB), eight million volunteers donate about 15 million units of whole blood each year. Each donated unit of blood is tested for infectious diseases including hepatitis, HIV and other retroviruses.

Important Product Usage and Safety Information

The ABBOTT PRISM HTLV-I/HTLV-II test (human T-lymphotropic virus Types I and II) can be used by laboratory technicians to screen individual donations of blood and plasma for antibodies to human T -- lymphotropic virus Type I and/ or human T -- lymphotropic virus Type II (anti-HTLV-I/HTLV-II). This assay has not been validated for use with pooled specimens. The assay is not intended for use on cord blood specimens or for the laboratory diagnosis of HTLV-I/HTLV-II infection. This product contains human sourced and/or potentially infectious components.

About ABBOTT PRISM

The PRISM instrument consolidates testing into a single system automating many of the manual testing procedures and steps currently used to screen blood. Safety features built into the system help track and monitor each sample throughout the testing process providing documentation and quality control for testing facilities. The PRISM system can run 160 samples per hour, making it possible to test more than 1,200 samples per eight-hour shift.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott to Present at JP Morgan Healthcare Conference
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Abbott Declares 336th Consecutive Quarterly Dividend
4. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
5. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
6. Abbott Scientists Create One Molecule With Two Antibody Functions
7. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
8. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
9. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
10. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
11. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):